title: SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts.
abstract: A new non-cytotoxic therapy that SOM230 (pasireotide)，a somatostatin analogue (SSTA) combined with celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor was tested in nude mice bearing HepG2 xenografts. Two agents did not markedly arrest the growth of HepG2 cells but greatly down-regulated vascular endothelial growth factor expression. An imbalance between the vigorous demand and insufficient supply of nutrients and oxygen for tumor growth resulted in the massive necrosis of xenografts. The combination synergistically induced the early apoptosis of HepG2 cells and achieved longest survival without adverse reaction. This impressive strategy appears promising as a systemic therapy for patients with hepatocellular carcinoma (HCC).
authors.affiliation: West China School of Medicine, Sichuan University, Chengdu.
authors.forename: Yan
authors.initials: Y
authors.lastname: Xie
authors.forename: Shuang
authors.initials: S
authors.lastname: Chen
authors.forename: Chun-Hui
authors.initials: CH
authors.lastname: Wang
authors.forename: Cheng-Wei
authors.initials: CW
authors.lastname: Tang
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000068579:Celecoxib; D049109:Cell Proliferation / Q000187:drug effects; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects; D004357:Drug Synergism; D056945:Hep G2 Cells; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009336:Necrosis; D011720:Pyrazoles / Q000008:administration & dosage / Q000494:pharmacology*; D017481:Receptors, Somatostatin / Q000378:metabolism; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D017481:Receptors, Somatostatin; D013449:Sulfonamides; D042461:Vascular Endothelial Growth Factor A; C103631:somatostatin receptor 3; C101130:somatostatin receptor type 1; D013004:Somatostatin; C094573:somatostatin receptor 5; C517782:pasireotide; D000068579:Celecoxib